WALTHAM, Mass. — BostonGene has been named Innovator of the Year at the 2025 Life Sciences Times Vanguard Awards, recognizing the company’s work developing integrated AI foundation models designed to accelerate oncology drug development.
The Waltham-based company said the award highlights its approach to addressing one of the industry’s most persistent challenges: the high failure rate and inefficiency in cancer drug development. BostonGene’s platform is designed to move beyond traditional fragmented methods by offering a more comprehensive biological understanding of both tumors and the immune system.
“We are incredibly honored to be named Innovator of the Year by the Life Sciences Times Vanguard Awards,” said Andrew Feinberg, President and CEO of BostonGene. “This award validates our conviction that achieving depth—a mechanistic understanding of both the tumor and the immune system—is the only way to effectively de-risk the oncology pipeline. Our AI platform provides the decision-ready evidence needed to increase probability of success, shorten development cycles, and confidently bring life-changing therapies to patients faster.”
At the core of the company’s platform are omnimodal foundation models that integrate genomics, transcriptomics, spatial biology, and proteomics into a unified system. This framework powers what the company calls its Digital Twin, a tool designed to simulate treatment responses and predict therapeutic outcomes with greater accuracy.
BostonGene said the platform enables pharmaceutical research teams to conduct in silico hypothesis testing, improve clinical trial design through patient stratification, and make earlier go or no-go decisions during development. The company added that these capabilities are already being used by partners to improve efficiency and increase the probability of technical success across oncology programs.
As predictive modeling becomes more central to drug development, BostonGene said it aims to position its platform as a core decision engine for oncology research, helping bring new therapies to market more efficiently.
